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Abstract
Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result in cytokine storm, systemic inflam-
matory response and coagulopathy that is prognostic of poor outcomes. While some, but not all, laboratory findings appear 
similar to sepsis-associated disseminated intravascular coagulopathy (DIC), COVID-19- induced coagulopathy (CIC) appears 
to be more prothrombotic than hemorrhagic. It has been postulated that CIC may be an uncontrolled immunothrombotic 
response to COVID-19, and there is growing evidence of venous and arterial thromboembolic events in these critically ill 
patients. Clinicians around the globe are challenged with rapidly identifying reasonable diagnostic, monitoring and antico-
agulant strategies to safely and effectively manage these patients. Thoughtful use of proven, evidence-based approaches must 
be carefully balanced with integration of rapidly emerging evidence and growing experience. The goal of this document is to 
provide guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding 
use of anticoagulant therapies in patients with COVID-19. We discuss in-hospital and post-discharge venous thromboem-
bolism (VTE) prevention, treatment of suspected but unconfirmed VTE, laboratory monitoring of COVID-19, associated 
anticoagulant therapies, and essential elements for optimized transitions of care specific to patients with COVID-19.
Keywords Anticoagulation · COVID-19 · Direct oral anticoagulant · Prophylaxis · Stewardship · Venous thromboembolism
Highlights
• Many patients with COVID-19 are at increased risk of 
venous thromboembolism (VTE). Therefore, we rec-
ommend pharmacologic prophylaxis for patients with 
COVID-19 when hospitalized.
• We recommend that dosing of VTE pharmacologic 
prophylaxis be evidence-based, whenever possible. Esca-
lated doses can be considered for critically ill patients.
• We recommend that post-hospital pharmacologic prophy-
laxis be used selectively for patients at highest risk for 
VTE based on existing evidence from randomized trials.
• We recommend the use of anti-Xa assay rather than aPTT 
to monitor unfractionated heparin dosing due to potential 
baseline abnormlaities in aPTT for patients with COVID-
19.
• We recommend a full 3 month course of therapeutic anti-
coagulation for patients with COVID-19 who are pre-
sumed to have a hospital-associated VTE event.
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Introduction and methods
Reports of elevated risk of thrombosis associated with coro-
navirus disease-19 (COVID-19) have led frontline providers 
to consider the empiric use of therapeutic anticoagulation for 
hospitalized patients even in the absence of documented or 
clinically suspected thrombosis. High-quality evidence in 
this clinical area is absent. As such, providers should employ 
a methodical and thoughtful approach to the use of high-risk 
anticoagulant medications for both prophylactic and thera-
peutic purposes.
This guidance document addresses key issues pertaining 
to prevention or treatment of thrombotic events in hospital-
ized patients with COVID-19 with the overarching purpose 
of striking a balance between risks and benefits of antico-
agulation therapies. The document also addresses key strate-
gies to minimize COVID-19 exposure risk for patients tak-
ing chronic anticoagulant medications.
This guidance is predicated on (1) the shared experiences 
of medical providers managing COVID-19 from early stages 
across the globe, (2) expert opinions from the Anticoagula-
tion Forum Board of Directors and (3) known best prac-
tices that have long-served as the evidence-based founda-
tion of anticoagulation management in the pre-COVID-19 
era. Given the highly dynamic nature of this pandemic, it 
is essential to apply rational evidence-based approaches 
whenever possible, stay apprised of emerging evidence and 
modify practice accordingly.
In this document, the use of specific language points to 
the strength of our guidance statements. Practices for which 
there is the strongest evidence and/or nearly unanimous 
expert opinion are described as “we recommend.” Practices 
for which there is less strong evidence and/or lack of con-
sensus are described as “we suggest.” Finally, practices for 
which little to no evidence exists and/or there is lack of con-
sensus are described as “is reasonable.”
Recommendations in this document are, whenever pos-
sible, based on the latest available evidence. However, read-
ers are cautioned that for some issues, published evidence 
is inconclusive, unavailable, or evolving. In all instances, 
recommendations represent the opinion(s) of the authors 
and are not to be solely relied upon or used as a substi-
tute for careful medical judgments by qualified medical 
professionals.
Questions
(1) Should acutely ill hospitalized patients 
with confirmed or highly suspected COVID‑19 
receive venous thromboembolism (VTE) 
prophylaxis?
Acutely ill patients hospitalized with pneumonia, with or 
without COVID-19, possess several established risk factors 
for VTE including acute respiratory illness, active infec-
tion, an inflammatory state and diminished mobility. These 
patients may have additional clinical risk factors for VTE, 
such as advanced age (e.g., > 65 years), cancer, obesity, 
pregnancy, congestive heart failure, or history of prior VTE. 
Most, if not all, would qualify for in-hospital VTE prophy-
laxis according to existing evidence-based guidelines [1–3]. 
As COVID-19 itself may be associated with a prothrombotic 
state [4–6], VTE prophylaxis is of utmost importance. Addi-
tionally, more severely ill patients with COVID-19 who are 
admitted to the intensive care unit (ICU) may have severe 
mobility limitations as a result of being intubated, sedated, 
paralyzed, and potentially placed in a prone position. An 
early study out of the Hubei Province in China [7] suggests 
that in the absence of VTE prophylaxis, 25% of COVID-19 
patients developed lower extremity DVT as assessed by sur-
veillance doppler ultrasound of the lower extremities, which 
is higher than the 5–15% incidence seen in placebo arms of 
early studies of VTE prevention in medically ill hospitalized 
patients [8–10]. In these early studies, use of pharmacologic 
VTE prophylaxis reduced the incidence of VTE by up to 
60% without an increase in major bleeding. A second study 
from the Netherlands found pulmonary embolism (PE) in 
25 of 184 ICU patients with COVID-19 (13.6%), 72% of 
which were in central, lobar, or segmental pulmonary arter-
ies, which occurred despite standard dose pharmacologic 
prophylaxis [11]. A third study from Italy identified throm-
boembolic events (venous and arterial) in 7.7% of patients 
admitted with COVID-19, estimating a cumulative rate of 
21% [12]. While each of these studies are limited in their 
design, data collection, and/or statistical methodology, the 
importance of VTE prophylaxis cannot be understated for 
hospitalized patients with this illness.
Recommendations
(a) We recommend pharmacologic VTE prophylaxis 
for all hospitalized non-pregnant patients with con-
firmed or highly suspected COVID-19, regardless of 
VTE risk assessment score (e.g. IMPROVE [13], Padua 
[14], Caprini [15]) unless a contraindication exists (e.g. 
active bleeding, profound thrombocytopenia).
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(b) We recommend pharmacologic VTE prophylaxis 
for all hospitalized pregnant patients with confirmed 
or highly suspected COVID-19. Providers should fol-
low guidance recently published by the Royal College 
of Obstetricians (RCOG) [16]. Close collaboration with 
obstetric and anesthesiology colleagues is recommended 
in the event of delivery and/or need for epidural anesthe-
sia during hospitalization.
(c) In patients with a contraindication to pharmacologic 
VTE prophylaxis, we recommend consistent applica-
tion of intermittent pneumatic compression devices with 
regular re-assessment for conversion to pharmacologic 
prophylaxis.
(d) In critically ill patients, it is reasonable to employ both 
pharmacologic and mechanical VTE prophylaxis (i.e., 
intermittent pneumatic compression devices) as long as 
no contraindication to either modality exists.
(2) What intensity of VTE prophylaxis should 
patients with COVID‑19 receive?
To the best of our knowledge, all published studies regard-
ing VTE prophylaxis in patients with COVID-19 have been 
conducted in adult critically ill patients. Thus, there is no 
evidence to suggest that approaches other than standard 
regimens recommended in existing VTE prevention guide-
lines are indicated for non-critically ill patients. In the study 
by Klok et al. [11] conducted among critically ill patients 
with COVID-19 in three ICUs across the Netherlands, the 
investigators found 25 symptomatic VTE events in 184 adult 
patients, all of whom received pharmacologic VTE prophy-
laxis. It should be noted that 2 of the 3 ICUs initially used 
lower than standard doses of low molecular weight heparin, 
and the doses were increased over time. Age and coagulopa-
thy were independent predictors of thrombotic complica-
tions. This study suggests that critically ill adult COVID-19 
patients may develop VTE with standard pharmacologic 
prophylaxis. A study of 150 patients with COVID-19 and 
acute respiratory distress syndrome (ARDS) from 4 ICUs 
in France receiving prophylactic (80%) or empiric treat-
ment dose (20%) anticoagulation found 16.7% of patients 
suffered pulmonary embolism (PE) despite this therapy [17]. 
This represents nearly a sixfold increase in PE compared 
to patients with ARDS not related to COVID-19. Indirect 
evidence from other populations, such as bariatric surgery, 
trauma, and critical illness associated with H1N1 influenza, 
suggests intensified prophylaxis regimens (either subcutane-
ous or low-intensity infusion) may be safe and effective if 
reasonably applied to critically ill patients with COVID-19 
[18–22]. At this time there is no evidence for use of bio-
markers such as D-dimer to guide intensification of antico-
agulant dosing despite it being a marker of poor prognosis 
[23]. However, it is important for providers and clinicians 
to stay apprised of emerging evidence and adjust practices 
accordingly.
Recommendations
(a) For all non-critically ill hospitalized patients (i.e., not 
in an ICU) with confirmed or highly suspected COVID-
19, we recommend standard dose VTE prophylaxis as per 
existing societal guidelines for medically ill and surgical 
hospitalized patients. Dose adjustments for renal function 
or extremes of weight should follow product labeling and/
or institutional protocols.
(b) For critically ill patients (i.e., in an ICU) with con-
firmed or highly suspected COVID-19, we suggest 
increased doses of VTE prophylaxis (e.g., enoxaparin 
40 mg subcutaneous twice daily, enoxaparin 0.5 mg/kg 
subcutaneous twice daily, heparin 7500 units subcuta-
neous three times daily, or low-intensity heparin infu-
sion [22, 24]). This suggestion is based largely on expert 
opinion. Dose adjustments for renal function or extremes 
of weight should follow product labeling and/or institu-
tional protocols. Individual hospitals should determine 
which regimens best align with institutional experience 
and workflow. Several examples of institutional protocols 
for COVID-19 are available for review and use within 
the Anticoagulation Forum’s Centers of Excellence 
Resources Center (https ://acfor um-excel lence .org/Resou 
rce-Cente r/index .php).
(c) For pregnant patients with confirmed or highly sus-
pected COVID-19, we recommend that providers col-
laborate closely with obstetric and anesthesia colleagues 
to determine optimal VTE prophylaxis dosing. Interme-
diate dosing regimens often used in the third trimester, 
as suggested by the American college of Obstetrics and 
Gynecology (ACOG) [25] and RCOG [26], may be a 
reasonable option for pregnant patients with COVID-19.
(d) We recommend against using biomarker thresholds, 
such as elevated D-dimer, as the sole reason to trigger 
escalations in anticoagulant dosing outside the setting of 
a clinical trial.
(e) For patients that are improving and transferring out 
of the ICU to the medical ward, it is reasonable to de-
escalate to standard VTE prophylaxis dosing.
(3) Should patients with confirmed COVID‑19 
receive VTE prophylaxis after hospital discharge?
The 2018 American Society of Hematology Guidelines on 
VTE Prevention in Medically Ill Patients [2] and the 2012 
American College of Chest Physicians Guidelines on VTE 
Prevention in Non-surgical Patients [27] recommend against 
extending VTE prophylaxis beyond hospital discharge based 
on a balance of potential risk and benefit even in highly select 
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patients [28]. Despite two FDA-approved agents for this indi-
cation (betrixaban, rivaroxaban) [29, 30], extending VTE 
prophylaxis beyond hospital discharge has not been widely 
adopted due to logistical challenges with implementation, 
bleeding risk, and large numbers needed to treat to prevent 
a single VTE event. There is no direct evidence for extended 
VTE prophylaxis in COVID-19 patients to inform this ques-
tion. Severely ill patients with COVID-19 may experience 
prolonged hospital stay, significant deconditioning, and the 
post-ICU syndrome which greatly limits or delays full recov-
ery to baseline mobility or health status by time of discharge. 
In addition, patients with COVID-19 may be discharged early 
in their recovery while they remain quite ill in order to free up 
hospital beds for sicker patients, particularly in regions hard-
hit by the pandemic.
Consideration for post-hospital VTE prophylaxis may be 
reasonable on a case-by-case basis for patients with COVID-
19 who are low bleed risk (e.g., IMPROVE bleed score < 7.0 
[31]) and:
• Were admitted to the ICU, intubated, sedated, and possibly 
paralyzed for multiple days
• Have ongoing VTE risk factors at the time of discharge 
(e.g., diminished mobility, profound weakness, not at base-
line physical status)
Recommendations
(a) We suggest that extended VTE prophylaxis is not nec-
essary for all patients with COVID-19 who are being dis-
charged from the hospital.
(b) We suggest that a multidisciplinary discussion occur at 
or near the time of discharge to determine if a patient has 
ongoing VTE risk factors, may benefit from extended post-
hospital VTE prophylaxis, and has ensured access to VTE 
prophylactic medications.
(c) We recommend using a standardized patient selection 
approach that mirrors clinical trial populations as closely 
as possible (see Table) and that involves the patient in the 
decision-making process.
(d) If post-discharge prophylaxis is deemed reasonable, we 
recommend use of an adequately studied and/or approved 
agent such as betrixaban [29], or rivaroxaban [30], or 
enoxaparin (adjusted as need based on weight, renal/liver 
function, and drug-drug interactions) and suggest limiting 
the total duration as used in the clinical trials (i.e. enoxa-
parin 6-14 days; rivaroxaban 31-39 days; betrixaban 35-42 
days) (see Table 1).
(4) Which assay should be used to monitor 
unfractionated heparin in patients with COVID‑19?
Patients with COVID-19 who have a suspected or con-
firmed VTE may require unfractionated heparin (UFH) 
during their hospitalization. The aPTT and anti-Xa activ-
ity are commonly used assays to monitor UFH. Studies 
have shown that the aPTT is prolonged at baseline in some 
patients with COVID-19, which could make it an unreli-
able modality for safely and effectively managing heparin 
in patients with COVID-19 [23]. Moreover, some patients 
with COVID-19, particularly those with critical illness, 
may exhibit heparin resistance as measured by the aPTT 
because of very high levels of fibrinogen and factor VIII.
Recommendations
(a) We suggest use of low molecular weight heparin 
(LMWH) over UFH for the treatment of confirmed 
or suspected VTE whenever possible in patients with 
COVID-19. This approach avoids additional laboratory 
monitoring, minimizes nursing and phlebotomy expo-
sure, and limits use of personal protective equipment.
(b) Due to lack of evidence on outcomes for bleeding or 
thrombosis, we do not recommend dosing adjustments 
of LMWH using anti-Xa levels [32].
(c) We recommend use of UFH over LMWH in patients 
with acute kidney injury or creatinine clearance less 
than 15-30 ml/min.
(d) We recommend using an anti-Xa assay rather than 
an aPTT to monitor therapeutic UFH in patients with 
COVID-19 whose aPTT is prolonged at baseline. If the 
baseline aPTT is normal, it is reasonable to monitor 
therapeutic UFH with either an anti-Xa assay or aPTT. 
We suggest that clinicians consider possible reasons 
(other than COVID-19) for baseline aPTT prolongation, 
as this laboratory finding could be due to an underlying 
coagulopathy that increases the risk of anticoagulant-
associated bleeding.
(e) We suggest using an anti-Xa assay rather than an 
aPTT to monitor therapeutic UFH in patients with 
COVID-19 who exhibit heparin resistance (typically 
defined as need for >35,000 units of heparin per 24 
hours) as measured by the aPTT. If a patient does not 
exhibit heparin resistance, it is reasonable to monitor 
therapeutic UFH with either an anti-Xa assay or aPTT. 
Guidance for establishing Anti-Xa monitoring of hepa-
rin infusion is provided at the Anticoagulation Forum 
Centers of Excellence https ://acfor um-excel lence .org/
Resou rce-Cente r/.
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(5) Should biomarkers, such as D‑dimer, be serially 
measured to trigger changes in care?
While D-dimer elevation and other biomarkers have been 
associated with worse outcomes in patients with COVID-19 
[23, 33, 34], it is unknown if intensification of anticoagu-
lant therapy based on biomarker thresholds alone improves 
patient outcomes.
Recommendations
(a) Based on currently available evidence, we suggest 
against daily monitoring of d-dimer for the purpose 
of guiding anticoagulant therapy. D-dimer measure-
ment may be used as a marker of illness severity and 
prognosis.
(b) We suggest against intensification of anticoagu-
lant dosing based only on biomarkers, such as d-dimer. 
However, acutely worsening clinical status in con-
junction with laboratory value changes, such as ris-
ing D-dimer, may necessitate further thromboembolic 
workup or empiric treatment.
(c) We recommend providers and clinicians stay 
apprised of emerging evidence regarding biomarkers 
of thromboembolic risk and adjust practices accord-
ingly.
(6) Should thrombolytic therapy be used in patients 
with COVID‑19?
A recent case series of three patients with COVID-
19 and ARDS-related respiratory failure who received 
alteplase 50 mg (25 mg bolus followed by 25 mg IV over 
2 h) reported improvements in oxygenation. However, 
the effects were transient [35]. Systemic administration 
of thrombolytics for PE has been associated with major 
bleeding and intracranial hemorrhage rates of almost 10% 
and 1–2%, respectively [36]. Thrombolytic therapy is 
not recommended for the vast majority of patients with 
PE given limited efficacy data in patients who are hemo-
dynamically stable [37, 38]. There is currently no high-
quality evidence for administering alteplase or any other 
thrombolytic for the treatment of COVID-19 pulmonary 
microthrombi. The risk for adverse events is high.
Table 1  Select post-hospital VTE prophylaxis trials [29, 30]
CrCl creatinine clearance, P-gp P-glycoprotein, VTE venous thromboembolism, NYHA new york heart association, ULN upper limit of normal, 
BMI body mass index
MAGELLAN APEX
Study drugs Rivaroxaban 10 mg daily for 31–39 days
Enoxaparin 40 mg daily for 6–14 days
Betrixaban 160 mg once, then 80 mg daily for 35–42 days
Enoxaparin 40 mg daily for 6–14 days
Dose adjustment None Betrixaban 80 mg once, then 40 mg daily if CrCl 15–29 ml/min or 
concurrent use of strong P-gp inhibitor
Key inclusion criteria Age ≥ 40 years
Hospitalized for acute medical illness
Reduced mobility for ≥ 4 days
Risk factors for VTE
Age ≥ 40
Hospitalized for acute medical illness
Reduced mobility for ≥ 3 days
Risk factors for VTE
Key medical illnesses Heart failure (NYHA Class III or IV)
Active cancer
Acute ischemic stroke
Acute infectious or inflammatory disease
Acute respiratory insufficiency
Acutely decompensated heart failure
Acute respiratory failure
Acute infectious disease
Acute rheumatic disease
Acute ischemic stroke
Additional risk factors Severe varicosities
Chronic venous insufficiency
History of cancer
History of VTE
History of heart failure (NYHA class III/IV)
Thrombophilia
Recent major surgery or trauma 
(6–12 weeks)
Hormone replacement therapy
Age ≥ 75 years
Obesity (BMI ≥ 35)
Acute infectious disease contributing to 
hospitalization
Age ≥ 75 years, or
Age 60–74 years with D-dimer ≥ 2 times the ULN, or
Age 40–59 with D-dimer ≥ 2 times the ULN and prior VTE or cancer
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Recommendations
(a) We recommend against use of thrombolytics in 
patients with COVID-19 outside of a clinical trial 
setting unless there is another clinical indication for 
thrombolysis, such as ST elevation myocardial infarc-
tion, acute ischemic stroke, or high-risk (massive) PE 
with hemodynamic compromise
(7) How should VTE prophylaxis be administered 
in pediatric patients with COVID‑19?
Thromboembolic events are rare occurrences in children. 
When they do occur, it is most often in hospitalized patients 
with multiple prothrombotic risks factors (e.g. infection, 
inflammation, dehydration, surgery, immobility, vascular 
access devices, estrogen, or an inherited thrombophilia). As 
a consequence, many pediatric tertiary-care hospitals have 
developed venous thromboembolism (VTE) prevention clin-
ical pathways to assess risk for thrombosis in their patients 
and to recommend non-pharmaceutical and pharmaceutical 
interventions for pediatric patients at moderate and high risk 
for VTE.
Reports from China and the US suggest that most pedi-
atric cases are asymptomatic or mild and that the need for 
hospitalization is rare [39]. Consequently, the pediatric 
experience caring for infants and children with COVID-19 
in hospitals is limited with the most being in places such 
as New York, where large numbers of COVID-19 patients 
(adult and pediatric) have presented for care.
Recommendation
We suggest that pediatric patients admitted for COVID-
19 who are moderately or severely ill be given VTE risk 
prophylaxis in accordance with existing institutional 
guidelines.
(8) What specific transitions of care elements 
are important to address at the time of hospital 
discharge for patients with COVID‑19 who 
are continuing prophylactic or therapeutic 
anticoagulation after hospital discharge?
Transitions from the hospital to the outpatient setting are 
important timepoints to re-assess therapies and ensure ade-
quate communication between clinicians, the patient, and 
families or caregivers. Specific to patients with COVID-19, a 
few issues should be addressed during these critical junctures. 
In many centers, access to diagnostic imaging for VTE may 
be limited for patients with COVID-19. However, following 
a few days of therapeutic anticoagulation, thrombus may not 
always be detected on delayed imaging even if it was present 
initially. This significantly limits the role of delayed imaging 
to determine if continued empiric anticoagulation is appropri-
ate for patients who were treated empirically. Other key ele-
ments include thorough evaluation for any clinically relevant 
drug-drug interactions between prescribed anticoagulants and 
COVID-19 therapies, clear documentation of intended dura-
tion of anticoagulation therapy and ensuring access to pre-
scribed therapies prior to discharge.
Recommendations
(a) We recommend thorough evaluation for any clinically 
relevant drug-drug interactions in patients with COVID-
19 who require concomitant anticoagulation. In addition to 
screening for common drug-drug interactions, it is impor-
tant to screen for interactions with COVID-19-specific 
therapies (e.g. antivirals) via regularly updated reliable 
resources. A suggested resource may be accessed at https 
://www.covid 19-drugi ntera ction s.org/
(b) We recommend a full 3-month course of anticoagula-
tion for any patients initiated on therapeutic anticoagula-
tion for a presumed thrombus in whom rapid imaging is 
not feasible. A possible exception would be a patient who 
experienced recent bleeding or is at a high risk of bleeding. 
Anticoagulation beyond the initial 3-month period should 
be determined in accordance with existing guidelines for 
presumed hospital-associated VTE events [40].
(c) In patients receiving empiric anticoagulation for a pre-
sumed but unconfirmed VTE, we suggest that delayed 
imaging not be used to determine if anticoagulation can be 
stopped before completing a three-month course.
(d) We recommend that all patients be assessed for prehos-
pital use of anticoagulation and that re-initiation of anti-
coagulation prior to discharge be based on a combination 
of pre-existing conditions (e.g., atrial fibrillation) and their 
COVID-19-related hospital course.
(e) We recommend that all elements of an anticoagulation 
stewardship transition of care be included for patients with 
COVID-19 prior to hospital discharge on an anticoagulant. 
This includes (but is not limited to) clear documentation 
of the indication (e.g., empiric treatment of highly sus-
pected COVID-related VTE), intended duration of therapy, 
appropriate anticoagulation education, referral and follow-
up appointment scheduled prior to discharge. (Access the 
Anticoagulation Forum Core Elements of Anticoagulation 
Stewardship Programs Guide may be accessed at https ://
acfor um.org/web/educa tion-stewa rdshi p.php).
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(9) When should patients on chronic warfarin 
therapy be transitioned to a direct oral 
anticoagulant (DOAC) in the setting of the COVID‑19 
pandemic?
Many patients who take chronic warfarin therapy are con-
cerned about the potential risk of COVID-19 exposure while 
managing their warfarin. Specifically, patients may have 
concerns about exposure risk while providing the laboratory 
a sample for measurement of their prothrombin time interna-
tional normalized ratio (INR) and/or when interacting with 
their anticoagulation provider. For many patients, providing 
reassurance about appropriate preventative measures (e.g., 
wearing a mask, washing hands, maintaining social distance) 
may be sufficient. However, other patients may be eligible to 
switch to DOAC therapy, thereby reducing the need for fre-
quent laboratory draws. Care must be taken to select appro-
priate patients for whom DOAC therapy is indicated and can 
be initiated and maintained. Careful assessment of weight, 
renal function, liver function, drug interactions, indication 
for anticoagulation, and in-depth review of the year-round 
cost implications should be performed prior to switching 
from warfarin to a DOAC.
Recommendations
(a) We recommend that anticoagulation clinics use stand-
ardized educational materials for their warfarin-treated 
patients about safety precautions when obtaining INR 
blood draws to reduce the risk of COVID-19 infection
(b) We recommend that patients who would not be eligi-
ble for DOAC therapy prior to the COVID-19 pandemic 
not be switched to DOAC therapy during the COVID-19 
pandemic. This includes (but is not limited to) patients 
with mechanical heart valves, severe liver dysfunction, or 
combined renal dysfunction and/or drug-drug interactions 
that preclude safe DOAC use. Ability to reliably obtain 
and take DOACs is another important consideration when 
assessing eligibility to switch.
(c) We suggest that clinics interested in transitioning 
patients from warfarin to a DOAC develop a standardized 
screening protocol to identify eligible patients.
(d) We suggest that patients taking chronic oral antico-
agulant in the outpatient setting be switched to shorter 
acting agents (e.g., LMWH or UFH) when initially hos-
pitalized for COVID-19 in case of clinical deterioration, 
changes in renal function, or need for invasive procedures.
(10) How can COVID‑19 exposure risk be minimized 
for patients on chronic warfarin therapy?
Although switching to a DOAC is an attractive option for 
patients requiring long-term anticoagulation, many patients 
will either need to remain on warfarin due to DOAC con-
traindications or will choose not to switch. For these 
patients, warfarin must be safely managed during and after 
the COVID-19 pandemic. Frequent trips to the laboratory 
or anticoagulation clinic increases the risk of COVID-19 
exposure and/or transmission. However, insufficient INR 
monitoring and warfarin dose management increases the 
risk of bleeding and thromboembolism.
Strategies that minimize the risk of COVID-19 exposure 
for warfarin patients are critical and may include:
Transition to a DOAC if possible
Referral for patient self-testing
Extended interval INR monitoring
Use of face masks, social distancing and good hand 
hygiene before, after and during the laboratory or clinic 
visit
Seeking care at ‘non-respiratory’ clinics that are not see-
ing patients with upper respiratory tract infection symp-
toms
Avoiding busy laboratory times, such as Mondays or 
weekday mornings
Use of drive-up fingerstick INRs
A number of randomized and observational studies have 
demonstrated the safety in using extended INR testing inter-
vals (> 4 weeks) for patients with stable warfarin manage-
ment [41–43]. This approach can be considered for select 
patients without changes in warfarin dosing for three or more 
months. Patient self-testing PST could also be considered 
for suitable patients and would allow for more frequent test-
ing without increasing the risk of exposure. Candidates for 
PST should have adequate vision and dexterity to accurately 
perform the test. Patients with antiphospholipid antibod-
ies and those with conditions resulting in chronically high 
(i.e. > 55%) or low (i.e. < 30%) hematocrit levels may not 
have reliable fingerstick INR test results. Finally, several 
anticoagulation clinics have established drive-up fingerstick 
INR monitoring so patients do not need to enter the clinic. 
Anticoagulation clinics already employing fingerstick INR 
testing are particularly well-positioned for drive-up INR 
testing.
Recommendations
(a) We suggest that for patients on chronic warfarin 
management who have had stable INRs for at least three 
months, extending the INR testing interval up to twelve 
weeks can be considered.
(b) We suggest that anticoagulation clinics that provide 
face-to-face management explore the option of “drive-up” 
INR point-of-care testing.
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(c) We recommend that patients who require INR testing 
be encouraged to work with their providers and laborato-
ries to minimize their COVID-19 risk rather than omit-
ting or delaying INR testing.
(d) We recommend patient self-testing for patients who 
demonstrate testing competency and who can afford this 
option.
Conclusion
While evidence is rapidly emerging about COVID-19-as-
sociated coagulopathy and thrombosis risk, there is little 
high-quality evidence to guide antithrombotic management. 
The present recommendations aim to provide guidance for 
frontline clinicians caring for patients with COVID-19 and/
or patients with chronic thrombotic conditions requiring 
ongoing management in the era of the COVID-19 pandemic. 
Whenever possible, we recommend that clinicians rely on 
pre-COVID evidence-based principles of anticoagulation 
management combined with rational approaches to address 
unprecedented clinical challenges. As this area is rapidly 
evolving, it will be necessary to integrate additional evi-
dence into our management recommendations. Fortunately, 
several clinical studies, including randomized controlled tri-
als, are being conducted; the results will better inform our 
management decisions. Online resources, such as the Anti-
coagulation Forum Centers of Excellence Resource Center 
(https ://acfor um-excel lence .org/) will be helpful in gathering 
and dissemination of these findings.
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